{"article_link": "https://www.frontiersin.org/articles/10.3389/fonc.2023.1186858/full", "data": [{"id": "data_1", "omics": "Transcriptomics", "link": "https://xenabrowser.net/datapages/", "format": "Processed Data", "source": "University of California Santa Cruz (UCSC)", "public_id": "TCGA-BRCA RNA-seq"}, {"id": "data_2", "omics": "Genomics", "link": "https://xenabrowser.net/datapages/", "format": "Processed Data", "source": "University of California Santa Cruz (UCSC)", "public_id": "TCGA-BRCA CNV"}, {"id": "data_3", "omics": "Epigenomics", "link": "https://xenabrowser.net/datapages/", "format": "450k array", "source": "University of California Santa Cruz (UCSC)", "public_id": "TCGA-BRCA DNA methylation"}, {"id": "data_4", "omics": "Transcriptomics", "link": "http://www.ncbi.nlm.nih.gov/geo/", "format": "Processed Data", "source": "Gene Expression Omnibus (GEO)", "public_id": "GSE7390"}, {"id": "data_5", "omics": "Transcriptomics", "link": "http://www.ncbi.nlm.nih.gov/geo/", "format": "Processed Data", "source": "Gene Expression Omnibus (GEO)", "public_id": "GSE20685"}, {"id": "data_6", "omics": "Transcriptomics", "link": "http://www.ncbi.nlm.nih.gov/geo/", "format": "Single-cell RNA-seq", "source": "Gene Expression Omnibus (GEO)", "public_id": "GSE176078"}, {"id": "data_7", "omics": "Transcriptomics", "link": "http://www.ncbi.nlm.nih.gov/geo/", "format": "Single-cell RNA-seq", "source": "Gene Expression Omnibus (GEO)", "public_id": "GSE103091"}, {"id": "data_8", "omics": "Genomics", "link": "https://www.cancerrxgene.org/", "format": "Processed Data", "source": "Genomics of Drug Sensitivity in Cancer (GDSC)", "public_id": "GDSC"}], "analyses": [{"id": "analysis_1", "analysis_type": "Hub genes screening", "analysis_data": ["data_1", "data_2", "data_3"], "training_set": [], "test_set": [], "label": {"p_combined_threshold": ["< 0.010"]}}, {"id": "analysis_2", "analysis_type": "Construction and validation of RS signature", "analysis_data": ["data_1", "data_2", "data_3"], "training_set": [], "test_set": [], "label": {"risk_group": ["high-risk", "low-risk"], "method": "Median-based risk stratification"}}, {"id": "analysis_3", "analysis_type": "Kaplan-Meier (KM) analysis", "analysis_data": ["analysis_2"], "training_set": [], "test_set": [], "label": {"risk_group": ["high-risk", "low-risk"]}}, {"id": "analysis_4", "analysis_type": "Receiver Operating Characteristic (ROC) analysis", "analysis_data": ["analysis_2"], "training_set": [], "test_set": [], "label": {"risk_group": ["high-risk", "low-risk"]}}, {"id": "analysis_5", "analysis_type": "Comparison of RS with clinical indicators", "analysis_data": ["analysis_2"], "training_set": [], "test_set": [], "label": {"clinical_factors": ["age", "T", "N", "M", "TNM stage"]}}, {"id": "analysis_6", "analysis_type": "Stratification analysis by TNM stages", "analysis_data": ["analysis_2"], "training_set": [], "test_set": [], "label": {"TNM_stage": ["I/II", "III/IV"]}}, {"id": "analysis_7", "analysis_type": "Stratification analysis by molecular subtypes", "analysis_data": ["analysis_2"], "training_set": [], "test_set": [], "label": {"molecular_subtype": ["ER-negative", "ER-positive", "PR-negative", "PR-positive", "HER2-negative", "HER2-positive"]}}, {"id": "analysis_8", "analysis_type": "Stratification analysis in TNBC patients", "analysis_data": ["analysis_2", "data_7"], "training_set": [], "test_set": [], "label": {"molecular_subtype": ["TNBC", "non-TNBC"]}}, {"id": "analysis_9", "analysis_type": "Single-cell data analysis", "analysis_data": ["data_6"], "training_set": [], "test_set": [], "label": {"risk_group": ["high-risk", "low-risk"]}}, {"id": "analysis_10", "analysis_type": "Immune checkpoint analysis", "analysis_data": ["analysis_2"], "training_set": [], "test_set": [], "label": {"risk_group": ["high-risk", "low-risk"]}}, {"id": "analysis_11", "analysis_type": "Drug sensitivity analysis", "analysis_data": ["analysis_2", "data_8"], "training_set": [], "test_set": [], "label": {"risk_group": ["high-risk", "low-risk"]}}], "results": [{"analysis_id": "analysis_3", "metric": "p-value", "value": "<0.001", "features": null}, {"analysis_id": "analysis_4", "metric": "AUC", "value": "3-year AUC: 0.738; 5-year AUC: 0.701", "features": null}, {"analysis_id": "analysis_5", "metric": "AUDC", "value": "3-year AUDC: 0.008; 5-year AUDC: 0.023", "features": null}, {"analysis_id": "analysis_6", "metric": "p-value", "value": "Stage I/II: <0.001; Stage III/IV: 0.001", "features": null}, {"analysis_id": "analysis_7", "metric": "p-value", "value": "ER-negative: <0.001; PR-negative: <0.001; HER2-negative: <0.001", "features": null}, {"analysis_id": "analysis_8", "metric": "p-value", "value": "Training set: 0.023; GSE103091: 0.003", "features": null}, {"analysis_id": "analysis_8", "metric": "AUC", "value": "Training set: 3-year AUC: 0.665; 5-year AUC: 0.666; GSE103091: 3-year AUC: 0.719; 5-year AUC: 0.713", "features": null}, {"analysis_id": "analysis_9", "metric": "Cellular composition difference", "value": "Overall cells and lymphocytes composition differ between high-risk and low-risk patients", "features": null}, {"analysis_id": "analysis_10", "metric": "Expression difference", "value": "Down-regulated expressions of immune checkpoints in high-risk TNBC patients", "features": ["BTLA", "CD200R1", "CD27", "CD28", "CD40", "CD40LG", "CTLA4", "HLA-DRB1", "IL2RB", "LAG3", "PDCD1", "TIGIT", "TNFRSF14"]}, {"analysis_id": "analysis_11", "metric": "IC50 difference", "value": "Decreased sensitivity to most drugs in high-risk subgroup, except for BI2536 which showed increased sensitivity", "features": ["BI2536", "Camptothecin", "Epirubicin", "Vinnorelbine"]}]}